Besides bladder cancer, during the past two decades, GPX1 Pro198Leu polymorphism has been extensively studied in other cancer types [53], mainly breast [54], prostate [55], lung [56], leukemia [57], and colon cancers [58]. This evidence concerns the gene GPX1 and urinary bladder carcinoma.